Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol's editorial on biosimilars of follitropin alfa

Drug Discov Today. 2023 May;28(5):103524. doi: 10.1016/j.drudis.2023.103524. Epub 2023 Feb 23.

Authors

Fernando de Mora¹, Colin M Howles²

Affiliations

¹ Departament of Pharmacology, Therapeutics and Toxicology, Universidad Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
² ARIES Consulting, Ch du Barbolet 5b, 1213 Onex, Geneva, Switzerland.

PMID: 36828193
DOI: 10.1016/j.drudis.2023.103524

No abstract available

Publication types

Editorial

MeSH terms

Biosimilar Pharmaceuticals*
Follicle Stimulating Hormone, Human
Randomized Controlled Trials as Topic
Recombinant Proteins

Substances

follitropin alfa
Biosimilar Pharmaceuticals
Follicle Stimulating Hormone, Human
Recombinant Proteins